Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, sold AVTX on Aug 17, 2026
Prices as of Oct 16 · price update delayed · Every feed →
▼ SELL$74.8K3,749 shares at $19.94Christopher Ryan Sullivan Chief Financial OfficerAVTX Avalo Therapeutics, Inc.
- Traded
- Aug 17, 2026
- Disclosed
- Aug 19, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
AVTX since disclosure
−45.7%
after the sale
Similar stocks (XLV) since disclosure
+0.6%
XLV — its sector index fund
Change in closing price from Aug 19, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLChristopher Ryan Sullivan Chief Financial OfficerAVTX Avalo Therapeutics, Inc.$622Kdisclosed Aug 19 · filed 1 day after the trade
- ▼ SELLChristopher Ryan Sullivan Chief Financial OfficerAVTX Avalo Therapeutics, Inc.$753Kdisclosed Aug 19 · filed 2 days after the trade